

CLAIMS

The following listing of claims will replace all previous versions of claims presented in this application:

1. - 40. (Canceled).

41. (Currently amended) ~~The method of claim 39, wherein said indolinone is~~
A method of extending corneal graft survival following corneal transplantation in a patient, comprising administering to said patient an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of 3(2,4-dihydroxy-benzylidene)-1,3-dihydro-indol-2-one; 3-(3-fluoro-4-methoxy-benzylidene)-1,3-dihydro-indol-2-one; and 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one.

42. (Currently amended) The method of claim 41, where said ~~indolinone compound~~
compound is 3(2,4-dihydroxy-benzylidene)-1,3-dihydro-indol-2-one.

43. (Currently amended) The method of claim 41, where said ~~indolinone compound~~
compound is 3-(3-fluoro-4-methoxy-benzylidene)-1,3-dihydro-indol-2-one.

44. (Currently amended) The method of claim 41, where said ~~indolinone compound~~
compound is 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one.

45. (Currently amended) The method of ~~claim 39~~ claim 41, further comprising administering to said patient an anti-angiogenic agent.

46. (Currently amended) The method of ~~claim 39~~ claim 41 or claim 45, further comprising administering to said patient an immunosuppressive agent.

47. (Currently amended) The method of ~~claim 39~~ claim 41, wherein said pharmaceutical composition is administered prior to corneal transplantation.

48. (Currently amended) The method of ~~claim 39~~ claim 41, wherein said pharmaceutical composition is administered subsequent to corneal transplantation.

49. (Currently amended) The method of ~~claim 39~~ claim 41, comprising administering to said patient an effective amount of ~~[[a]]~~ the pharmaceutical composition ~~comprising a VEGFR-3 kinase inhibitor~~ two or more times.

50. (Previously presented) The method of claim 49, comprising repeated administration over a period of at least one month.

51. (Previously presented) The method of claim 49, comprising repeated administration over a period of at least six months.

52. (Currently amended) The method of claim 49, comprising:

(a) administering to said patient prior to corneal transplantation ~~comprising a VEGFR-3 kinase inhibitor~~ [[a]] the pharmaceutical composition; and

(b) administering to said patient subsequent to corneal transplantation ~~comprising a VEGFR-3 kinase inhibitor~~ [[a]] the pharmaceutical composition,
whereby lymphangiogenesis is suppressed in the cornea of said patient.

53. (Previously presented) The method of claim 39, comprising systemic administration of said pharmaceutical composition.

54. (Previously presented) The method of claim 39, comprising local administration of said pharmaceutical composition.

55. (Previously presented) The method of claim 54, comprising topical administration of said pharmaceutical composition.

56. (Previously presented) The method of claim 54, comprising local injection of said pharmaceutical composition.

57. (Previously presented) The method of claim 54, said pharmaceutical composition released from an intraocular or periorbital implant.